TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05049044

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
Study: NCT03504098

Intervention type: BEHAVIORAL
Intervention: nutrition consult
Description: Post-lung cancer operation diet pattern
Study: NCT03751839

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biochemical Tests
Description: The investigators will perform blood tests in every participant.
Study: NCT02945332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Required supervised walking
Description: The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-required supervised walking
Description: The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Flex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Flex
Study: NCT03366922

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artemisia Annua, Moringa oleifera
Description: As described above

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia Annua, Moringa oleifera
Description: As described above

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia Annua, Moringa oleifera
Description: As described above
Study: NCT05049044

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
Study: NCT00387894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
Study: NCT01556126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amphilimus Eluting Stent (CRE8)
Description: Sirolimus formulated coronary eluting stent
Study: NCT04137354

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent placebo iron supplement
Description: Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent placebo iron supplement
Description: Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent iron supplement
Description: Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent iron supplement
Description: Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vitamin A
Description: Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Vitamin A
Description: Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-dose Vitamin A supplement
Description: Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-dose Vitamin A supplement
Description: Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
Study: NCT01171092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib and G-CSF
Description: Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily
Study: NCT05795530

Intervention type: PROCEDURE
Intervention: cochlear implantation
Description: surgery for bilateral hearing loss
Study: NCT03685838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Description: Class II above knee compression stockings
Study: NCT04062448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420 mg will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 will be administered intravenously.
Study: NCT03168568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/Sacubitril or placebo
Description: tablet (double dummy)
Study: NCT05049044

Intervention type: OTHER
Intervention: Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description: The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
Study: NCT01174056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: 600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pioglitazone placebo
Description: Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone placebo
Description: Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Zileuton placebo
Description: Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton placebo
Description: Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: PPAR-gamma agonist
Study: NCT00680875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Click City
Description: School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
Study: NCT03751839

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Osteodensitometry
Description: The investigators will perform an osteodensitometry in every participant.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Tests
Description: The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
Study: NCT03168568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan or placebo
Description: tablet (double dummy)
Study: NCT01271569

Intervention type: DRUG
Group type: OTHER
Intervention: Fospropofol disodium
Description: Fospropofol disodium： 0.5g
Study: NCT04558190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Lipid infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Lipid infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Lipid infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Oral administration of MitoQ capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Beta2-agonist infusion
Study: NCT03751839

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-QCT
Description: The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
Study: NCT01923298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Study: NCT02216656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580 low dose
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580 middle dose
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580 high dose
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN1493
Description: Oral administration
Study: NCT02482714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity.
Description: Have subject do moderate physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity.
Description: Have subject do moderate physical activity.
Study: NCT03741374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-invasive non-surgical therapy (MINST)
Description: A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
Study: NCT01800773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
Study: NCT03745976

Intervention type: PROCEDURE
Intervention: questionnaire and Xray for all patients
Description: questionnaire and Xray for all patients
Study: NCT02497040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: local injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: local injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: local injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: local injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: local injection
Study: NCT01303406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01990131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Health Education Training
Study: NCT04333407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75mg
Description: • If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg
Description: • If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
Study: NCT03446014

Intervention type: DEVICE
Intervention: Fitbit Sub-Study

Intervention type: DEVICE
Intervention: Fitbit Sub-Study
Study: NCT04333407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 MG
Description: * If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~* If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: • If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: • If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
Study: NCT02125942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Central Meditation and Imagery Therapy
Description: mindfulness, guided imagery, meditation
Study: NCT03503864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Arsenic trioxide（ATO） is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.
Study: NCT00809471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 30 minutes orally prior to initiation of sexual activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 30 minutes orally prior to initiation of sexual activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 30 minutes orally prior to initiation of sexual activity
Study: NCT01514058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA first, followed by CRCP with bilinary stenting
Description: EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with stent placement, followed by EUS-FNA
Description: ERCP with stent placement, followed by EUS-FNA
Study: NCT03902184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH4102
Description: Patients will receive a flat dose of 750mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH4102
Description: Patients will receive a flat dose of 750mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH4102
Description: Patients will receive a flat dose of 750mg
Study: NCT03950596

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Needle Core Biopsy
Description: Core Biopsy will be taken from the quadriceps femoris muscle

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Needle Core Biopsy
Description: Core Biopsy will be taken from the quadriceps femoris muscle
Study: NCT01968525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pre-oxygen
Description: 3 min of preoxygenation before anesthesia induction.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pre-oxygen
Description: 3 min of preoxygenation before anesthesia induction.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pre-oxygen
Description: 3 min of preoxygenation before anesthesia induction.
Study: NCT03243422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Successful aging health education intervention
Description: The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hearing intervention
Description: The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.